VRDN FY 2025 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$3B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$71M+23359.9% YoY

Gross Profit

$70M98.4% margin

Operating Income

-$363M-512.9% margin

Net Income

-$343M-483.6% margin

EPS (Diluted)

$-3.32

Cash Flow

Operating Cash Flow

-$276M

Free Cash Flow

-$277M

Stock-Based Comp.

$44M

Balance Sheet

Total Assets

$899M

Total Liabilities

$177M

Stockholders' Equity

$722M

Cash & Equivalents

$212M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$71M	$302,000	+23359.9%
Gross Profit	$70M	$302,000	+22975.8%
Operating Income	-$363M	-$299M	-21.5%
Net Income	-$343M	-$270M	-26.9%